SCM
VRDN icon

Silverarc Capital Management’s Viridian Therapeutics VRDN Stock Holding History

Silverarc Capital Management’s Portfolio VRDN Stock Details VRDN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-348,569
Closed -$10.8M – 91
2025
Q4 		$10.8M Buy
348,569
+89,060
+34% +$2.44M 1.51% 21
2025
Q3 		$5.6M Buy
+259,509
New +$4.68M 0.76% 34
2025
Q1 		– Sell
-100,000
Closed -$1.92M – 82
2024
Q4 		$1.92M Buy
+100,000
New +$2.17M 0.42% 46
2024
Q1 		– Sell
-50,438
Closed -$1.1M – 98
2023
Q4 		$1.1M Buy
50,438
+3,000
+6% +$47.4K 0.33% 59
2023
Q3 		$728K Buy
47,438
+2,438
+5% +$46.5K 0.22% 66
2023
Q2 		$1.07M Buy
45,000
+8,619
+24% +$221K 0.33% 57
2023
Q1 		$926K Buy
36,381
+33,381
+1,113% +$1.07M 0.38% 59
2022
Q4 		$87.6K Buy
+3,000
New +$69.1K 0.03% 87
2022
Q2 		– Sell
-126,136
Closed -$2.33M – 82
2022
Q1 		$2.33M Buy
126,136
+2,330
+2% +$44.8K 0.97% 27
2021
Q4 		$2.45M Buy
123,806
+17,728
+17% +$330K 0.99% 33
2021
Q3 		$1.75M Buy
106,078
+77,679
+274% +$1.14M 0.99% 37
2021
Q2 		$519K Buy
28,399
+813
+3% +$13.9K 0.23% 81
2021
Q1 		$461K Buy
+27,586
New +$516K 0.25% 74

Other funds holding VRDN

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.75B AUM 68.58% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
FFM
Fairmount Funds Management West Conshohocken, Pennsylvania $1.51B AUM 546.08% 1-Year Est. Return
VA
VR Adviser New York $3.3B AUM 525.74% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
PBA
Paradigm Biocapital Advisors New York $5.34B AUM 380.18% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

Silverarc Capital Management's VRDN Position: Q1 2026 in Review

Silverarc Capital Management sold out of Viridian Therapeutics (VRDN) in Q1 2026, closing a stake of 348,569 shares — an estimated $10.8M sold.

Silverarc Capital Management first reported a position in VRDN in Q1 2021 and held it in 13 quarters. The position peaked at $10.8M in Q4 2025. 225 funds tracked by Wall St. Rank hold VRDN as of Q1 2026.

  • Silverarc Capital Management reported no remaining Viridian Therapeutics position as of Q1 2026 after selling out during the quarter.
  • Silverarc Capital Management sold 348,569 Viridian Therapeutics shares in Q1 2026, an estimated $10.8M.
  • Silverarc Capital Management first reported a position in Viridian Therapeutics in Q1 2021 and held it in 13 quarters.
  • Silverarc Capital Management's Viridian Therapeutics position peaked at $10.8M in Q4 2025.
  • 225 funds tracked by Wall St. Rank held Viridian Therapeutics as of Q1 2026.

Based on Silverarc Capital Management's 13F filing for Q1 2026, filed 14 May 2026.